Campus researchers identify promising new target for cancer treatment : dailycal

as informed in dailycal

Campus researchers identify promising new target for cancer treatment

Campus researchers identify promising new target for cancer treatment

Researchers at UC Berkeley published a study Wednesday detailing a potential new target for cancer drugs lying behind a "secret compartment" of a common protein complex.In order to locate the target, researchers probed the origins of proteins that stimulate cellular growth and found that many come from a surprising location — a usually blocked section of the protein complex eIF3.According to Jamie Cate, a campus professor of molecular and cell biology who led the study, new treatments for cancer could focus on closing the door to reduce the growth of cancerous cells.Certain protein molecules can play a role in the development of cancer, said Amy Lee, an assistant professor at Brandeis University who co-authored the study during her time as a UC Berkeley postdoctoral scholar.


let alone mirror

NHS to fast-track new cancer drugs after shake-up to £340m fund

NHS to fast-track new cancer drugs after shake-up to £340m fund

Four breakthrough cancer drugs will be fast-tracked to NHS patients under the revamped Cancer Drugs Fund (CDF).The CDF fast tracks cancer drugs which are not yet routinely available to patients but show potential.The previous fund was closed amid fears spiralling costs had made it unsustainable.NHS England said the new medicines will benefit 4,500 patients, with access speeded by up to four months – but critics say further reform is needed on how the government negotiates with drug companies.


moreover from fiercepharma

On day one of cancer fund overhaul, NICE faces new calls for reform

On day one of cancer fund overhaul, NICE faces new calls for reform

Today is the first day for England's drug cost watchdog to take the reins of the beleaguered Cancer Drugs Fund and the moment it took over, NICE faced criticism from a top drugmaker over how it intends to run the fund.Under the new setup, NICE is tasked with deciding which meds currently funded by the CDF will stay and which will go.But in a statement, Roche said the U.K. government should overhaul NICE's review methodology "to stop patients facing ongoing anxiety around the availability of existing and new cancer medicines."While 37 of 39 indications remain on the CDF and will be reviewed by NICE, Roche pointed out that the 10 of those had previously been rejected for NHS use under the "unreformed appraisal system," based on their cost-effectiveness."This could mean that thousands more cancer patients are denied medicines their doctors believe could be effective in their treatment," Roche UK general manager Richard Erwin said in a statement.